RECOMBINANT LEUKOCYTE INTERFERON ALPHA-2A AND MEDROXYPROGESTERONE IN ADVANCED RENAL-CELL CARCINOMA - A RANDOMIZED TRIAL

被引：62

作者：

STEINECK, G

STRANDER, H

CARBIN, BE

BORGSTROM, E

WALLIN, L

ACHTNICH, U

ARVIDSSON, A

SODERLUND, V

NASLUND, I

ESPOSTI, PL

NORELL, SE

机构：

[1] F HOFFMANN LA ROCHE & CO LTD, CH-4002 BASEL, SWITZERLAND

[2] KAROLINSKA INST, INST ENVIRONM MED, DEPT EPIDEMIOL, S-10401 STOCKHOLM 60, SWEDEN

[3] KAROLINSKA HOSP, DEPT UROL, S-10401 STOCKHOLM 60, SWEDEN

[4] KAROLINSKA HOSP, DEPT DIAGNOST RADIOL, S-10401 STOCKHOLM 60, SWEDEN

来源：

ACTA ONCOLOGICA | 1990年 / 29卷 / 02期

关键词：

Advanced; Adverse effects; Anbibodies; Interferon; Liver enzymes; Medroxyprogesterone; Random allocation; Renal adenocarcinoma;

D O I：

10.3109/02841869009126537

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In a randomized study of advanced renal cell carcinoma 60 patients were allocated to treatment with either recombinant interferon alpha-2a or medroxyprogesterone acetate. Correlation between the dose of interferon alpha-2a and plasma-concentration indicated linear kinetics. Survival was similar in the two treatment groups. Only one complete and one partial response were seen in the interferon group and only one complete response in the medroxyprogesterone group, indicating a low therapeutic potential of both interferon and medroxyprogesterone. Interferon influenced the serum liver enzyme levels; increased transaminases were seen in 17 patients treated with interferon but in only four patients in the medroxyprogesterone group. Two patients had very high serum liver-enzyme levels concomitant with intolerable tiredness, in both patients the symptoms disappeared and the enzymes normalized after discontinuation of the interferon treatment. Antibodies to interferon developed frequently in patients receiving high dose oligomeric interferon therapy but rarely in patients receiving low dose monomeric interferon treatment. ©1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：155 / 162

页数：8

共 19 条

[1] INTERFERON THERAPY IN DISSEMINATED RENAL-CELL CARCINOMA [J].

EDSMYR, F ;

ESPOSTI, PL ;

ANDERSSON, L ;

STEINECK, G ;

LAGERGREN, C ;

STRANDER, H .

RADIOTHERAPY AND ONCOLOGY, 1985, 4 (01) :21-26

[2] PHASE-II STUDY OF HIGH-DOSE WEEKLY INTRAVENOUS HUMAN-LYMPHOBLASTOID INTERFERON IN RENAL-CELL CARCINOMA - A STUDY OF THE NATIONAL-CANCER-INSTITUTE-OF-CANADA CLINICAL-TRIALS GROUP [J].

EISENHAUER, EA ;

SILVER, HK ;

VENNER, PM ;

THIRLWELL, MP ;

WEINERMAN, B ;

COPPIN, CML .

BRITISH JOURNAL OF CANCER, 1987, 55 (05) :541-542

[3]

GALLATI H, 1982, J CLIN CHEM CLIN BIO, V20, P907

[4] THE DETECTION OF ANTIBODIES TO RECOMBINANT INTERFERON ALFA-2A IN HUMAN-SERUM [J].

HENNES, U ;

JUCKER, W ;

FISCHER, EA ;

KRUMMENACHER, T ;

PALLERONI, AV ;

TROWN, PW ;

LINDERCICCOLUNGHI, S ;

RAINISIO, M .

JOURNAL OF BIOLOGICAL STANDARDIZATION, 1987, 15 (03) :231-244

[5]

ITRI LM, 1987, CANCER, V59, P668, DOI 10.1002/1097-0142(19870201)59:3+<668::AID-CNCR2820591317>3.0.CO

[6]

2-J

[7]

KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO

[8]

2-L

[9]

KROWN SE, 1987, CANCER, V59, P647, DOI 10.1002/1097-0142(19870201)59:3+<647::AID-CNCR2820591313>3.0.CO

[10]

2-#

← 1 2 →